Lymphoma: A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab
Vedotin to Treat Non-Hodgkin Lymphomas
Will the antibody (a type of human protein) nivolumab help the body's immune system
to work against tumor cells?
Basic Study Information
Purpose:Location: cancer center
The purpose of this study is to test the effectiveness (how well the drug works),
safety, and tolerability of an investigational drug called nivolumab (also known as
BMS-936558) in combination with brentuximab vedotin. Nivolumab is an antibody (a type
of human protein) that is being tested to see if it will allow the body’s immune system
to work against tumor cells.
Brentuximab vedotin is an antibody-drug conjugate (a type of human protein linked
to a study drug). The antibody part of the drug binds to CD30 which often occurs on
diseased cells but rarely on normal tissues.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02581631?term=CA209-436&rank=1
Study Reference #: ILYM-15097
Lead Researcher (Principal Investigator)
Lead Researcher: Paul Barr
Study Contact InformationStudy Coordinator: Yelena Lerman
Phone: (585) 276-8333
Additional Study Details
Learn More About These Conditions
More information about Lymphoma, Non-Hodgkin
Trial Not Found
The study you are looking for is not active at this time.
Return to Search